Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting
November 23, 2022 07:55 ET
|
Senti Biosciences, Inc.
– Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment landscape and unmet need in AML – – Live and...
Senti Bio Reports Third Quarter Financial Results and Pipeline Updates
November 10, 2022 07:55 ET
|
Senti Biosciences, Inc.
- SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33and/or FLT3 expressing hematologic malignancies including MDS - - Selected development candidate for...
Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting
November 03, 2022 09:05 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Announces New Employment Inducement Grants
October 28, 2022 16:05 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting
October 05, 2022 08:01 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio to Participate in Chardan’s 6th Annual Genetic Medicines Conference
September 20, 2022 16:02 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio to Present at Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022 16:01 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Biosciences Announces New Employment Inducement Grants
August 19, 2022 16:05 ET
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using...
Senti Bio Reports Second Quarter Financial Results and Business Updates
August 15, 2022 16:05 ET
|
Senti Biosciences, Inc.
- Lead development candidate selected from SENTI-202 program; on track for IND filing in 2023 - - Expect to present CAR-NK cell therapy program data at multiple scientific conferences in 2022 - ...
Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits
June 09, 2022 07:30 ET
|
Senti Biosciences, Inc.
- Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million - - Combined company Senti...